Renew Biotechnologies

June 27, 2024

Renew Biotechnologies is a dynamic holding company dedicated to acquiring, developing, and commercializing impactful biotechnology. Our mission to explore and embrace groundbreaking technologies is propelling new frontiers of next-generation sequencing diagnostics in therapeutic areas that need it most. To accomplish this, we’re taking a unique approach. Unlike traditional venture capital or accelerator models, we drive the innovation ourselves leveraging disruptive sequencing technology developed by Renew’s R&D experts.

Renew currently operates 5 subsidiaries, each committed to creating solutions that address critical gaps in diagnostics. One key subsidiary, a next-generation sequencing lab specializing in nanopore sequencing and epigenetic analysis, enables the development of technologies for early disease detection and personalized medicine. Our current efforts target neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and ALS; women’s health challenges such as endometriosis and forensics; and pathogen detection for challenging infections such as Lyme disease. United by our dedication to accuracy and accessibility, our ventures collectively aim to impact global health—one breakthrough at a time.